50 closest statements
by meaning · ranked by similarity · 100 per pageMeaning search returns the 50 nearest statements, then applies your filters.
“Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1285% match
“Our mission is to discover and develop novel therapeutics to improve the lives of patients living with debilitating CNS disorders.”In use 2025 – now·1 sighting·SEC Form S-1/A, filed 2025-10-0673% match
“Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2272% match
“Our mission is to discover, develop and ultimately deliver medicines that are transformational for patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-2872% match
“Our mission is to improve the lives of patients suffering from CNS diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0271% match
“Our mission is to improve the lives of people touched by epilepsy, depression and other chronic disorders that may prove to be treatable with our VNS Therapy System.”In use 2007 – now·1 sighting·SEC Form 10-K, filed 2007-07-0671% match
“Our mission is to develop life-changing genetic medicines for people and their families impacted by devastating neurological diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2471% match
“Our mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0771% match
“Our mission is to create disease-modifying neurogenetic medicines by identifying validated targets, advancing multiple therapeutic modalities, and delivering them to the right areas within the central nervous system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1171% match
“Our mission is to develop and commercialize innovative medicines that change the course of the disease in patients who suffer from age-related brain disorders.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1371% match
“Our mission is to enable patients with these disorders to live fuller and healthier lives through the discovery and development of transformative therapies that overcome the key limitations of currently available treatments.”In use 2026 – now·1 sighting·SEC Form 424B4, filed 2026-08-1270% match
“Our mission is to develop and commercialize therapies with the potential to transform the lives of patients and their families living with rare diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0170% match
“Our mission is to provide transformative therapies to patient communities who have inadequate or no therapeutic options available to address these debilitating diseases.”In use 2022 – now·1 sighting·SEC Form 10-K, filed 2022-03-0870% match
“Our mission is to create, develop, manufacture, and deliver cell and gene therapies to transform the lives of people impacted by life-threatening diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-1869% match
“Our mission is to transform the lives of patients by creating medicines with improved therapeutic profiles for areas of unmet need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2369% match
“Our mission is to develop innovative therapies that can transform patients' lives by addressing areas of high unmet medical need.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2369% match
“Our mission is to accelerate transformative therapies to improve the lives of people living with cancer and other serious diseases.”In use 2017 – now·1 sighting·SEC Form 10-K, filed 2017-02-2369% match
“Our mission is to make our products and research services available to our clients for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs.”In use 2023 – now·1 sighting·SEC Form 10-K, filed 2023-10-1369% match
“Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2669% match
“Our mission is to build a leading, fully integrated global rare disease company using our patient-centric approach to identify and develop life-transforming medicines for the treatment of severe rare diseases.”In use 2023 – now·1 sighting·SEC Form 20-F, filed 2023-04-1969% match
“Our mission is to create transformative gene-based medicines for serious human diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1269% match
“Our mission is to develop transformative therapies that prevent and eliminate metabolic disease.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-2469% match
“Our mission is to empower physicians globally to deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination protocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-05-1469% match
“Our mission is to be the global leader and pioneer of this new treatment paradigm, integrating recombinant technology, gene therapy and cell therapy to address the challenges of targeting and delivering effective therapies, including to the brain for cancer and other central nervous system (“CNS”) indications.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2868% match
“Our mission is to build a community and company capable of sustainably discovering, developing and delivering to patients innovative, important new medicines that will make a material difference in their health, well-being and lives.”In use 2009 – now·1 sighting·SEC Form 10-K, filed 2009-03-1368% match
“Our mission is to improve the lives of patients living with serious and under-addressed neurological, neuro-endocrinology and psychiatry related diseases and disorders.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-02-0568% match
“Our mission is to develop therapeutic drugs designed to treat neurodegenerative diseases, currently focusing on Parkinsonian and other movement disorders.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-08-2868% match
“Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-09-2568% match
“Our mission is to discover and develop novel therapeutic drugs to treat diseases and disorders for which there are no adequate therapies or for which a new drug would represent a significant advancement over the current therapy.”In use 2003 – now·1 sighting·SEC Form 10-K, filed 2003-03-1468% match
“Our mission is to create and advance new medicines for patients suffering from serious and rare diseases that are underserved by today’s therapies.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2668% match
“Our mission is to transform patients’ lives by providing them with life-changing medicines which build on scientific breakthroughs in immunology.”In use 2025 – now·1 sighting·SEC Form 20-F, filed 2025-03-2068% match
“Our mission is to transform the lives of patients living with devastating genetic diseases by building the leading integrated genetic medicine company focused on developing and commercializing potentially curative therapeutics based on our GeneRide platform.”In use 2021 – now·1 sighting·SEC Form 10-K, filed 2021-03-1568% match
“Our mission is to provide superior treatment options for complex diseases and disorders to improve the lives of patients by developing innovative new medicines that exploit the unique role of NNRs.”In use 2012 – now·1 sighting·SEC Form 10-K, filed 2012-03-0668% match
“Our mission is to extend and enhance the lives of patients by discovering, developing, and commercializing novel pharmaceutical products for treating severe medical conditions.”In use 2007 – now·1 sighting·SEC Form 424B4, filed 2007-02-0768% match
“Our mission is to advance drug-free neuromodulation therapies that improve patient outcomes and reduce medication burden in complex disorders, while expanding access to effective care for populations with significant unmet needs.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-1967% match
“Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-1767% match
“Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients.”In use 2019 – now·1 sighting·SEC Form 10-K, filed 2019-03-0767% match
“Our mission is to deliver transformative therapeutics to those in need, and we believe our innovative EDO technology is well-positioned to effect this change for patients, families and the broader healthcare community.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-0467% match
“Our mission is to develop therapeutic products with the potential to address high unmet medical needs by identifying promising clinical-stage candidates and advancing their development to create products that will improve patients’ lives.”In use 2026 – now·1 sighting·SEC Form S-1, filed 2026-08-2167% match
“Our mission is to improve the lives of patients by accelerating the development of our customers’ drugs and devices through innovative solutions.”In use 2026 – now·1 sighting·SEC Form 20-F, filed 2026-05-2767% match
“Our mission is to develop therapies that empower the immune system to cure neurodegeneration and other diseases.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-2767% match
“Our purpose is to bring the power of biotherapeutics to the whole body, including the brain, by discovering, developing, and delivering medicines for people living with serious diseases.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-02-2667% match
“Our mission is to develop drugs that optimize health outcomes and improve patients’ quality of life.”In use 2026 – now·1 sighting·SEC Form 10-K, filed 2026-03-3167% match
“Our mission is to improve patient outcomes in the areas of neurodegenerative and oncological diseases by developing safe and effective cellular therapies that leverage the power of a patient’s immune system.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-10-0867% match
“Our mission is to build a leading oncology company that creates novel and transformative treatments for a wide range of oncology indications for which there are significant unmet medical needs.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-03-0767% match
“Our mission is to bring life-changing therapeutics to people living with rare diseases.”In use 2025 – now·1 sighting·SEC Form 10-K, filed 2025-03-1267% match
“Our mission is to improve the lives of patients and assist their care providers by delivering novel therapies that improve outcomes while reducing the undesirable side effects of many current therapies.”In use 2016 – now·1 sighting·SEC Form 10-K, filed 2016-03-1567% match
“Our mission is to be a global leader in generics, innovative medicines and biopharmaceuticals, improving the lives of patients.”In use 2024 – now·1 sighting·SEC Form 10-K, filed 2024-02-1267% match
“Our mission is to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.”In use 2026 – now·1 sighting·SEC Form 10-K/A, filed 2026-06-0267% match
“Our mission is to transform the lives of patients with chronic IMIDs through the development of oral, safe and effective small molecule product candidates.”In use 2026 – now·1 sighting·SEC Form S-1/A, filed 2026-01-2767% match
Showing 1–50 of 50